Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07495592 · ClinicalTrials.gov registry record · NA
The Acute Effects of Onnit Alpha Brain on Cognition and Mood States
A NA study, sponsored by Applied Science & Performance Institute.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT07495592: Completed NA study, sponsored by Applied Science & Performance Institute.
NCT07495592 is a NA study that has completed, run by Applied Science & Performance Institute. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07495592, a NA study, has completed, sponsored by Applied Science & Performance Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this randomized, double-blind, placebo-controlled crossover study is to evaluate the efficacy of the acute effects of an investigational supplement (Alpha Brain or Alpha Brain 2.0) on improving cognitive performance, vigilance, and subjective mood in healthy adults compared to placebo during a period of acute sleep deprivation under conditions of controlled sleep deprivation.
Primary Outcome
Subjects will complete the Psychomotor Vigilance Test (PVT), a sustained-attention reaction time task administered electronically via the Milliseconds platform for cognitive assessmentThe PVT yields multiple performance metrics including mean reaction time (milliseconds), number of lapses (reaction times exceeding 500 ms), and number of errors. Lower mean reaction times and fewer lapses and errors indicate better attentional performance and reduced cognitive fatigue.
Interventions
- DIETARY_SUPPLEMENT Alpha Brain proprietary cognitive dietary supplement
- DIETARY_SUPPLEMENT Alpha Brain 2.0 proprietary cognitive dietary supplement
- DIETARY_SUPPLEMENT Controlled Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2026-06-26 |
| Phase | NA |
What the finished NCT07495592 record still lists
NCT07495592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Alpha Brain proprietary cognitive dietary supplement is the first listed.
NCT07495592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07495592 about?
NCT07495592 is a clinical study titled "The Acute Effects of Onnit Alpha Brain on Cognition and Mood States". The purpose of this randomized, double-blind, placebo-controlled crossover study is to evaluate the efficacy of the acute effects of an investigational supplement (Alpha Brain or Alpha Brain 2.0) on improving cognitive performance, vigilance, and subjective mood in healthy adults compared to placebo...
What is the current status of trial NCT07495592?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2026-05-01. Estimated completion is 2026-06-26.
What interventions are being tested in trial NCT07495592?
The interventions under investigation include: Alpha Brain proprietary cognitive dietary supplement (DIETARY_SUPPLEMENT), Alpha Brain 2.0 proprietary cognitive dietary supplement (DIETARY_SUPPLEMENT), Controlled Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07495592?
This trial is sponsored by Applied Science & Performance Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07495592's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI